About ~ the publisher
About TB-500 Store: an instrument of record, not a storefront
What this site is, what the word in its name does and does not mean, and the standard every claim on it is held to.
What this site is
TB-500 Store is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site reads the published record the way an instrument reads a signal: one mechanism traced from the actin-binding motif to tissue-repair outcomes, each finding logged with its evidence class, and the regulatory status stated present-tense. Every quantitative claim is tied to a numbered citation you can verify.
What "Store" means here
The word "store" in the domain is editorial framing, not a claim about services. This site stores and organizes the research record on TB-500 — it is a repository of the literature, not a shop. Nothing is for sale here, nothing is dispensed, and no checkout, cart, or price appears anywhere on the site. The negative-space register of the design is deliberate: a research console, not a storefront.
We are explicit about this because the name could be read either way. Read it the way we mean it: a place the TB-500 literature is kept, sorted, and cited — a curated archive of what the studies measured.
The standard we hold to
Three rules govern the content. First, the fragment-versus-parent-protein distinction is never blurred: where a finding was measured on the ~4963 Da thymosin beta-4 protein rather than the ~889 Da Ac-LKKTETQ heptapeptide marketed as TB-500, we say so [5]. Second, we describe what was administered to which species at which dose by which route — never a dose for a person, because the compound is not intended for human consumption [16]. Third, we state the honest gaps as plainly as the findings: there are no completed controlled human trials of the fragment, and the tumor and angiogenesis signal is unresolved [11][9].
The regulatory facts on the TB-500 legal status page are drawn from an audited reference and cited to the FDA, stated present-tense, with no future agency action presented as a certainty.